Empaglinna Tablets 25/5 mg (Empagliflozin 2L-Proline, Linagliptin)
Empagliflozin 2L-Proline 37.766mg · Linagliptin Micronized 5mg
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
MFDS item code 202502559 · Approved 2025.09.26
Improvement of blood glucose control in patients with type 2 diabetes
This medication is used to help patients with type 2 diabetes who are taking empagliflozin and linagliptin together in managing their blood sugar levels. When taken along with diet control and exercise therapy, it helps in effectively managing blood sugar levels. This can contribute to smoother diabetes management and help in preventing complications.
The recommended starting dose is empagliflozin 10 mg (equivalent to 15.107mg of empagliflozin 2L-proline)/linagliptin 5 mg once daily. For patients who tolerate empagliflozin 10 mg/linagliptin 5 mg and require additional glycemic control, the dose of this medicine may be increased to 25/5mg (equivalent to 37.766mg of empagliflozin 2L-proline) once daily. Patients switching to this medicine from concomitant empagliflozin and linagliptin therapy should receive their previous doses. This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. However, if it is within 12 hours of the next dose, skip the missed dose and take the next dose at the usual scheduled time. Do not take a double dose in one day. Special populations Patients with renal impairment This medicine is not recommended for patients with an estimated glomerular filtration rate (eGFR) below 45 ml/min/1.73m2 for the purpose of improving glycemic control. No dosage adjustment is necessary in patients with an estimated glomerular filtration rate of 45 ml/min/1.73m2 or greater. Patients with hepatic impairment No dosage adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in these patients. Older adults No dosage adjustment based on age is necessary. In patients aged 75 years and older, renal function and the risk of volume depletion should be considered.
This medication should not be administered to certain patients. For example, those who are allergic to this medication's active ingredients, patients with type 1 diabetes, diabetic ketoacidosis, and those on dialysis should not take this medication. Patients with impaired kidney function must ensure their kidney function is checked before administration and should monitor their kidney status regularly after administration. The experience of using this medication in patients with heart failure is limited, so it should be used with caution. Acute pancreatitis may occur while taking this medication, so if symptoms such as severe abdominal pain appear, the medication should be stopped immediately, and a doctor should be consulted. Additionally, a skin condition known as bullous pemphigoid may appear, so any formation of blisters or erosion on the skin should be reported to healthcare professionals immediately. Urinary tract infections and genital infections can occur commonly when taking this medication. Women, in particular, are at a higher risk of infections, so prompt treatment should be sought if any symptoms of infection arise. There is a risk of hypoglycemia; therefore, when taken with insulin or sulfonylureas, blood sugar levels should be monitored carefully, and dosage adjustments may be necessary. Hypotension or dehydration due to fluid loss may occur, so elderly patients or those with low blood pressure should be particularly cautious, and if symptoms of dehydration occur, the administration of this medication may be temporarily halted. It is important to regularly check blood sugar levels, kidney function, and infection symptoms while taking this medication. Pregnant or breastfeeding women are advised not to use this medication, and if pregnancy is planned or occurs, a consultation with healthcare professionals should be mandatory. This medication should not be used in children under 18 years of age, as its safety and efficacy have not been established.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. The recommended storage temperature is between 1 and 30 degrees Celsius in a cool place. Storing it this way will help maintain the medication's effectiveness safely.
Light pink triangular film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 2L-Proline 37.766mg · Linagliptin Micronized 5mg
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
Empagliflozin 2L-Proline 15.107mg · Linagliptin Micronized 5mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
Empagliflozin 2L-Proline 37.766mg · Linagliptin Micronized 5mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
Empagliflozin 2L-Proline 15.107mg · Linagliptin Micronized 5mg
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.